Isoxsuprine%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520hydrochloride

# Isoxsuprine hydrochloride ## Overview Isoxsuprine hydrochloride is a vasodilator agent. Its exact mechanism of action is not fully understood but is believed to involve direct relaxation of vascular smooth muscle. ## Primary Indications * Treatment of peripheral vascular disease, such as intermittent claudication, and vasospastic disorders. ## Adult Dosing * Oral: 10 mg to 20 mg three to four times daily. Doses may be increased to 40 mg four times daily if individual response warrants. ## Pediatric Dosing * Safety and efficacy in pediatric patients have not been established. Use is generally not recommended. ## Dose Adjustments * No specific dose adjustments are typically required for renal or hepatic impairment, but caution and close monitoring are advised. ## Contraindications * Patients who have experienced a previous hypersensitivity reaction to isoxsuprine. * Use in patients with congenital heart disease or those requiring surgical intervention. ## Adverse Effects * Common: Nausea, vomiting, gastric distress, dizziness, weakness, flushing, headache, rash, hypotension. * Less Common: Tachycardia, palpitations, abdominal pain, drowsiness, nervousness. ## Key Drug Interactions * **Antihypertensives:** Isoxsuprine may potentiate the hypotensive effects of antihypertensive medications. Monitor blood pressure closely. * **Other Vasodilators:** Concurrent use with other vasodilators may increase the risk of hypotension. ## Monitoring * Monitor blood pressure and heart rate. * Assess for signs and symptoms of peripheral vascular disease improvement (e.g., pain relief, increased walking distance). * Observe for adverse effects. ## Clinical Pearls * Isoxsuprine is often discontinued if patient shows no symptoms or signs of clinical improvement after a reasonable period of trial. * Avoid administration in patients with recent arterial bleeding or glaucoma. * Patients should be advised to rise slowly from a sitting or lying position to minimize the risk of orthostatic hypotension. *** *Disclaimer: This information is intended for clinical decision-making and does not replace the need to consult the most current prescribing information, local protocols, and professional judgment.*